GILEAD SCIENCES SL
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
Phase 3
Completed
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Drug: LDV/SOF
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 111
- Registration Number
- NCT02613871
Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)
Phase 2
Terminated
- Conditions
- Primary Biliary Cirrhosis (PBC)
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 41
- Registration Number
- NCT02609048
- Locations
- 🇺🇸
Gastroenterology Associates of Western Michigan, PLC, d.b.a. West Michigan Clinical Research, Wyoming, Michigan, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇵🇱Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza w Bydgoszczy, Bydgoszcz, Kujawsko-pomorskie, Poland
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Phase 3
Completed
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 657
- Registration Number
- NCT02607956
- Locations
- 🇬🇧
St George's Healthcare NHS Trust, London, United Kingdom
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Canada
🇦🇺Prahran Market Clinic, Prahran, Victoria, Australia
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 943
- Registration Number
- NCT02607800
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 416
- Registration Number
- NCT02607735
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Phase 3
Completed
- Conditions
- HIV-1 Infection
- Interventions
- Drug: B/F/TAFDrug: ABC/DTG/3TCDrug: ABC/DTG/3TC PlaceboDrug: B/F/TAF Placebo
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 631
- Registration Number
- NCT02607930
- Locations
- 🇺🇸
Infectious Disease Specialists of Atlanta, Decatur, Georgia, United States
🇺🇸Prime healthcare services - St Michael's LLC d/b/a Saint Michael's medical center, Newark, New Jersey, United States
🇺🇸Augusta University, Augusta, Georgia, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
Phase 1
Terminated
- Conditions
- Metastatic Castrate-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 31
- Registration Number
- NCT02607228
Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
Phase 3
Completed
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 275
- Registration Number
- NCT02605954
- Locations
- 🇺🇸
Capital Medical Associates, P.C., Washington, District of Columbia, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
🇮🇹Azienda Ospedale San Paolo, Monza, Italy
Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed
Phase 3
Completed
- Conditions
- HIV-1 Infection
- Interventions
- Drug: B/F/TAFDrug: ABC/DTG/3TCDrug: ABC/DTG/3TC PlaceboDrug: B/F/TAF Placebo
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 567
- Registration Number
- NCT02603120
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults
Phase 3
Completed
- Conditions
- HIV-1 Infection
- Interventions
- Drug: B/F/TAFDrug: ATVDrug: DRVDrug: ATV/coDrug: DRV/coDrug: FTC/TDFDrug: ABC/3TC
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 578
- Registration Number
- NCT02603107
© Copyright 2025. All Rights Reserved by MedPath